4,601 articles
Sargramostim
Sargramostim, marketed as Leukine, is a recombinant GM-CSF drug approved in 1991 that speeds myeloid recovery after chemotherapy and bone marrow transplantation and improves survival after radiation exposure.
Sarizotan
Sarizotan (EMD 128130), a 5-HT1A agonist and dopamine D3/D4 ligand developed by Merck KGaA for levodopa dyskinesia; failed phase III trials and a Rett syndrome trial (STARS, NCT02790034), never approved.
Saroglitazar
Saroglitazar (Lipaglyn) is a dual PPAR α/γ agonist by Zydus, approved in India in 2013 for diabetic dyslipidemia and in 2020 for NAFLD; not FDA approved, with a PBC NDA under Priority Review.
Saruparib
Saruparib (AZD5305) is AstraZeneca's orally bioavailable, PARP1-selective PARP inhibitor and trapper (~500-fold selectivity over PARP2) for HRR-deficient breast, ovarian, pancreatic, and prostate cancers, in Phase III EvoPAR trials.
Sasanlimab
Sasanlimab (PF-06801591, proposed brand Zumrad) is Pfizer's subcutaneous anti-PD-1 IgG4 monoclonal antibody for bladder cancer; its phase 3 CREST trial met its EFS endpoint, but the EMA application was withdrawn in February 2026.
Satavaptan
Satavaptan (SR 121463, Aquilda) is a Sanofi-developed, highly selective vasopressin V2 receptor antagonist (vaptan class) for hyponatremia and cirrhotic ascites; it raised serum sodium in trials but failed phase III endpoints, showed higher mortality with diuretics, and was withdrawn in 2008, never approved.
Satralizumab
Satralizumab (Enspryng) is a humanized IgG2 anti-IL-6 receptor antibody approved from 2020 for AQP4-IgG-positive NMOSD in patients 12 and older, dosed 120 mg subcutaneously every 4 weeks after a three-dose loading phase.
Satraplatin
Satraplatin (JM216, BMS-182751, Orplatna) is an oral platinum(IV) prodrug chemotherapy agent developed for prostate and other cancers; it never gained FDA approval after its SPARC Phase III trial showed no overall survival benefit.
Satricabtagene autoleucel
Satricabtagene autoleucel (satri-cel, CT041, 恺力美) is CARsgen's autologous CLDN18.2-targeted CAR-T for gastric/GEJ cancer; approved by China's NMPA in June 2026 as the first CAR-T therapy for a solid tumor.
SATWAVPP trial
SATWAVPP (NCT04716868): Mexican randomized double-blind trial comparing Agave tequilana blue-variety fructans (Predilife) with psyllium plantago for functional constipation; 79 patients, 8 weeks, similar responder rates across four arms.
SAVE trial (NCT00738179)
SAVE trial (NCT00738179), Sleep Apnea cardioVascular Endpoints study, McEvoy et al NEJM 2016; randomized trial of CPAP in 2,717 nonsleepy OSA patients with cardiovascular disease; CPAP did not reduce cardiovascular events (HR 1.10) but improved sleepiness and quality of life.
Savolitinib
Savolitinib (volitinib, AZD6094, HMPL-504; Orpathys) is an oral, selective ATP-competitive MET tyrosine kinase inhibitor approved in China (2021) for MET exon 14-skipping NSCLC and developed with osimertinib for MET-amplified EGFR-mutant NSCLC and gastric cancer.
Saxagliptin anhydrous
Saxagliptin anhydrous (BMS-477118, CAS 361442-04-8) is the anhydrous form of saxagliptin, a DPP-4 inhibitor for type 2 diabetes marketed as the monohydrate; FDA approved 2009 as Onglyza, with increased heart failure hospitalization risk in SAVOR-TIMI 53.
Scopolamine
Scopolamine (hyoscine) is a tropane alkaloid muscarinic antagonist from Solanaceae plants, used mainly as the Transderm Scōp patch (FDA-approved 1979, first transdermal patch) to prevent motion sickness and postoperative nausea; side effects include dry mouth, drowsiness, and a 2025 FDA hyperthermia warning.
SCTV01C / Anningneng 2 (recombinant bivalent COVID-19 trimer protein vaccine)
SCTV01C (安诺能 2, Annuoneng 2) is Sinocelltech's bivalent recombinant S-trimer COVID-19 vaccine targeting Alpha and Beta variants with SCT-VA02B squalene adjuvant; EUA in China December 2022 as booster.
SCTV01E (recombinant tetravalent COVID-19 trimer protein vaccine)
SCTV01E (安诺能®4) is Sinocelltech's tetravalent recombinant S-trimer protein COVID-19 vaccine targeting Alpha, Beta, Delta, and Omicron BA.1; 30 µg with SCT-VA02B adjuvant, 69.4% efficacy, Chinese EUA March 2023.
Sebelipase alfa
Sebelipase alfa (Kanuma) is a recombinant human lysosomal acid lipase enzyme replacement therapy for LAL deficiency, including Wolman disease, produced in transgenic hen egg white; EU-approved August 2015, FDA December 2015.
Secnidazole
Secnidazole (Solosec) is a long-half-life 5-nitroimidazole antimicrobial given as a single 2 g oral dose for bacterial vaginosis and trichomoniasis; FDA-approved 2017 (BV) and 2021 (trichomoniasis), similar to metronidazole, possibly inferior to ornidazole.
Secobarbital
Secobarbital, known as quinalbarbitone in Britain and sold as Seconal in red capsules, is a short-acting barbiturate sleep medication discontinued in the United States in 2020.
Secretin synthetic human
Secretin synthetic human (ChiRhoStim, RG1068) is a synthetic 27-amino-acid copy of the human gut hormone secretin, FDA approved in 2004 to diagnose pancreatic exocrine dysfunction and gastrinoma and to aid ERCP; ineffective for autism.
Secukinumab
Secukinumab (Cosentyx, AIN457) is a fully human IgG1 monoclonal antibody inhibiting interleukin-17A, first approved 2014-2015 for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa.
Sedative
Sedative: drug that calms and reduces activity; hypnotics induce sleep. Classes include benzodiazepines, Z-drugs, barbiturates, orexin antagonists; GABA-A modulation; risks of dependence, respiratory depression, and opioid-involved overdose.
Sedomigene (NL003, Huasuoling) HGF plasmid
Sedomigene injection (Huasuoling, NL003, Donaperminogene Seltoplasmid) is a naked HGF plasmid gene therapy by Beijing Northland Biotech, approved by NMPA on 28 May 2026 for ischemic limb ulcers in severe lower limb ischemia.
Seladelpar
Seladelpar (Livdelzi) is a PPAR-delta agonist, 10 mg daily oral capsule for primary biliary cholangitis with inadequate UDCA response or intolerance; FDA accelerated approval August 2024, MHRA approval January 2025, NICE recommended 2026.
Selatogrel
Selatogrel (ACT-246475) is an investigational reversible P2Y12 inhibitor given subcutaneously, in Phase 3 (SOS-AMI, NCT04957719) for self-administration at suspected heart attack; developed by Idorsia, now Viatris.
SELECT - PsA 1 trial
SELECT-PsA 1 (NCT03104400), AbbVie-funded phase 3 trial of upadacitinib (Rinvoq) 15 and 30 mg versus placebo and adalimumab in 1,704 psoriatic arthritis patients with inadequate non-biologic DMARD response; ACR20 70.6/78.5% versus 36.2% placebo at week 12.
SELECT-NEXT trial
SELECT-NEXT (NCT02675426) was a phase 3 trial of upadacitinib 15 mg and 30 mg plus csDMARDs in rheumatoid arthritis with inadequate csDMARD response; 661 patients, ACR20 64-66% versus 36% placebo, 5-year extension data reported.
Selective organ targeting (SORT) of lipid nanoparticles
Selective organ targeting (SORT) is a lipid nanoparticle engineering strategy that redirects mRNA and CRISPR delivery from the liver to organs like the lungs and spleen.
Selective serotonin reuptake inhibitor
Selective serotonin reuptake inhibitors (SSRIs) are antidepressants, including fluoxetine, sertraline, and escitalopram, that block the serotonin transporter SERT; first approved with fluoxetine (Prozac) in December 1987.
Selegiline
Selegiline (L-deprenyl, Jumex, EMSAM) is the first selective irreversible MAO-B inhibitor, developed by Joseph Knoll; used for Parkinson's disease and, as a transdermal patch, major depressive disorder.